Efficacy of risdiplam in spinal muscular atrophy: A systematic review and meta-analysis
Autor
Pascual-Morena, Carlos
Martínez-Vizcaíno, Vicente
Cavero-Redondo, Iván
Martínez-García, Irene
Moreno-Herráiz, Nerea
Álvarez-Bueno, Celia
Saz-Lara, Alicia
Resumen
This systematic review and meta-analysis aimed to assess the efficacy and safety of risdiplam on motor and respiratory function in spinal muscular atrophy (SMA). We systematically searched Medline, Scopus, Web of Science, and the Cochrane Library from inception to March 2023. We included pre-post studies that determined the effect of risdiplam on the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND), the 32-item Motor Function Measure (MFM32), the Revised Upper Limb Module (RULM), the Hammersmith Functional Motor Scale – Expanded (HFMSE), respiratory function, and the proportion of risdiplam-related adverse events in a population with SMA (phenotypes 1 and 2/3). Meta-analyses were also performed where possible. Eleven studies were included. After 12 months of treatment, 57% of participants with SMA1 achieved a CHOP-INTEND score ≥ 40 points, and more than half were able to feed orally and had head control. In SMA2/3, MFM32, RULM, and HFMSE increased by 2.09 (1.17, 3.01), 1.73 (1.25, 2.20), and 1.00 (0.40, 1.59) points, respectively. Efficacy on respiratory function in SMA2/3 was inconsistent. Finally, 16% of participants experienced adverse events, but serious adverse events could not be quantified due to a lack of cases. The limited available evidence suggests that risdiplam is an effective and safe drug for the treatment of SMA. In addition, long-term clinical benefit may be partly determined by the stage of disease at which treatment is initiated. © 2023 The Authors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy published by Wiley Periodicals LLC on behalf of Pharmacotherapy Publications, Inc.
Colecciones
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Article
Effectiveness of Extracorporeal Shock Wave Therapy in Treatment of Spasticity of Different Aetiologies: A Systematic Review and Meta-Analysis (2024)
Otero-Luis, Iris; Cavero-Redondo, Iván; Álvarez-Bueno, Celia; Martinez-Rodrigo, Arturo; Pascual-Morena, Carlos; Moreno-Herráiz, Nerea; Saz-Lara, Alicia (Multidisciplinary Digital Publishing Institute (MDPI), 2024)Background: Spasticity is a motor disorder characterised by exaggerated movements of the tendons and accompanied by hyperreflexia and hypertonia. Extracorporeal shock wave therapy (ESWT) is used as a treatment for spasticity, ... -
Article
Exploring the Influence of Insulin Resistance on Arterial Stiffness in Healthy Adults: From the Metabolic and Cardiovascular Health Insights of the EVasCu Study (2024)
Pascual-Morena, Carlos; Cavero-Redondo, Iván; Martínez-García, Irene; Rodríguez-Gutiérrez, Eva; Lucerón-Lucas-Torres, Maribel; Moreno-Herráiz, Nerea; Díaz-Goñi, Valentina; Saz-Lara, Alicia (Multidisciplinary Digital Publishing Institute (MDPI), 2024)Previous evidence associates insulin resistance with arterial stiffness in various pathologies, yet limited reports exist in healthy adults. Therefore, this study aims to estimate the association between insulin resistance ... -
Article
Prevalence and genotypic associations of epilepsy in Prader-Willi Syndrome: A systematic review and meta-analysis (2024)
Pascual-Morena, Carlos; Martínez-Vizcaíno, Vicente; Cavero-Redondo, Iván; Álvarez-Bueno, Celia; Martínez-García, Irene; Rodríguez-Gutiérrez, Eva; Otero-Luis, Iris; del Saz-Lara, Andrea; Saz-Lara, Alicia (Academic Press Inc., 2024)Objective: To estimate the prevalence of epilepsy and febrile seizures and their association with genotype, i.e., 15q11-q13 deletions, uniparental chromosome 15 disomy (UPD) and other mutations, in the population with ...